[NH2:1][C:2]1[N:6]([CH:7]([CH2:9][CH2:10][CH2:11][CH2:12][CH2:13][CH3:14])[CH3:8])[N:5]=[C:4]([CH2:15][CH3:16])[C:3]=1[C:17]([NH2:19])=[O:18].[CH2:20]1[O:28][C:27]2[CH:26]=[CH:25][C:24]([CH2:29][C:30](OC)=O)=[CH:23][C:22]=2[O:21]1.CC(C)([O-])C.[K+].C(=O)([O-])O.[Na+]>ClCCl>[CH2:20]1[O:28][C:27]2[CH:26]=[CH:25][C:24]([CH2:29][C:30]3[NH:19][C:17](=[O:18])[C:3]4[C:4]([CH2:15][CH3:16])=[N:5][N:6]([CH:7]([CH2:9][CH2:10][CH2:11][CH2:12][CH2:13][CH3:14])[CH3:8])[C:2]=4[N:1]=3)=[CH:23][C:22]=2[O:21]110 mg (0.037 mmol) of 5-amino-3-ethyl-1-(2-octyl)-1H-pyrazole-4-carboxamide and 30 mg (0.129 mmol) of methyl 3,4-methylenedioxyphenylacetate are refluxed for 6 hours in 0.3 ml of a 0.5M ethanolic potassium tert-butoxide solution. After dichloromethane and saturated aqueous sodium hydrogen carbonate solution have been added, the phases are separated. Purification by chromatography gives 4 mg (25%) of a solid, Rf=0.76 (dichloromethane/methanol=15:1).